Estimating the Incidence of HIV Infection Among Men Who Have Sex With Men in Peru and Ecuador
NCT ID: NCT00279331
Last Updated: 2013-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2608 participants
OBSERVATIONAL
2006-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will last about 2 weeks. Medical history, a physical exam, an HIV rapid test, and HIV pre- and post-test counseling will occur at study entry. Those who test HIV positive will be asked to return to the test site in about 2 weeks to receive confirmatory test results. Patients confirmed to be infected with HIV will be referred to HIV treatment clinics in their area.
At study entry, participants will also undergo a syphilis test. Those who test positive for syphilis will receive same-day treatment at the clinic and be asked to return during Week 1 and 2 to complete treatment for sexually transmitted diseases (STDs) according to local guidelines. STD treatment will not be provided by the study. Those who test negative to both the HIV rapid test and the syphilis test at screening will not participate in any more study visits. Patients who consent to having samples stored for further investigations will also have their samples tested for HSV-2 infection following completion of the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male at birth
* Report having anal intercourse, either insertive or receptive, with another man 6 months prior to study entry
* Living in one of the participating study cities at time of study entry
* Self-report at least one of the following behaviors:
* No condom use during the last receptive or insertive anal intercourse
* Receptive or insertive anal intercourse with more than five sex partners 6 months prior to study entry
* Exchange of money, gifts, drugs, or shelter for sex 6 months prior to study entry
* STD symptoms 6 months prior to study entry
* Inconsistent condom use with an HIV infected sex partner 6 months prior to study entry
Exclusion Criteria
* Unwilling to participate in HIV screening
* Any psychiatric or mental condition that may interfere with the study
18 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Comprehensive International Program of Research on AIDS
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juan Guanira, MD, MPH
Role: STUDY_CHAIR
Asociación Civil Impacta Salud y Educación, Lima, Peru
Jorge Sanchez, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Asociación Civil Impacta Salud y Educación, Lima, Peru
Javier R. Lama, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Asociación Civil Impacta Salud y Educación, Lima, Peru
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fundación Ecuatoriana Equidad CIPRA CRS
Guayaquil-Guayas, , Ecuador
IMPACTA - Miraflores CIPRA CRS
Lima, , Peru
IMPACTA - Lince CIPRA CRS
Lima, , Peru
IMPACTA - San Miguel CIPRA Project 3B CRS
Lima, , Peru
Policlinico Daniel Alcides Carrión CIPRA CRS
Lima, , Peru
Asoc. de Servicios Generales de Salud y Educación CIPRA CRS
Sullana, , Peru
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bautista CT, Sanchez JL, Montano SM, Laguna-Torres VA, Lama JR, Sanchez JL, Kusunoki L, Manrique H, Acosta J, Montoya O, Tambare AM, Avila MM, Vinoles J, Aguayo N, Olson JG, Carr JK. Seroprevalence of and risk factors for HIV-1 infection among South American men who have sex with men. Sex Transm Infect. 2004 Dec;80(6):498-504. doi: 10.1136/sti.2004.013094.
Caceres CF, Mendoza W. Monitoring trends in sexual behaviour and HIV/STIs in Peru: are available data sufficient? Sex Transm Infect. 2004 Dec;80 Suppl 2(Suppl 2):ii80-4. doi: 10.1136/sti.2004.012021.
Goodreau SM, Goicochea LP, Sanchez J. Sexual role and transmission of HIV Type 1 among men who have sex with men, in Peru. J Infect Dis. 2005 Feb 1;191 Suppl 1(0 1):S147-58. doi: 10.1086/425268.
Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003 Jul 1;37(1):113-28. doi: 10.1086/375597. Epub 2003 Jun 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I-U19-AI053218-01A2
Identifier Type: -
Identifier Source: secondary_id
Project 3B
Identifier Type: -
Identifier Source: secondary_id
10408
Identifier Type: REGISTRY
Identifier Source: secondary_id
CIPRA PE 002
Identifier Type: -
Identifier Source: org_study_id